BioLoomics is thrilled to announce the addition of Dr. George Church to our Advisory Board. Often referred to as the father of synthetic biology, Dr. Church has made numerous advancements ...
Aaron Sato, PhD, joins the BioLoomics advisory board in February 2022. Aaron is the CSO of Twist Bioscience, a company enabling customer success through its offering of high-quality synthetic DNA ...
We are very excited to share the addition of Viswa Colluru, PhD to our advisory board. Viswa is the founder and CEO of Enveda Biosciences, a rapidly growing Biotech company ...
BioLoomics is excited to welcome Dr. Bill Kohlbrenner to the team as Vice President of Business Development. Prior to joining BioLoomics, Bill has had a fruitful career in pharma ...
Join us July 9th and 10th for the KAND Family & Scientific Engagement Conference hosted by KIF1A.ORG. Register here to join the conversation and learn about the latest research and ...
BioLoomics is joining KIF1A.ORG in its search for a treatment and cure for KIF1A-Associated Neurological Disorder (KAND). We are applying our evolution-in-a-microscope technology to build high throughput drug discovery ...
BioLoomics is forming a Scientific Advisory Board (SAB) to bring together diverse experts to bolster our mission to produce drug discovery assays and the first biosensing biologics with enhanced specificity ...
BioLoomics closed a $575,000 round of seed funding on May 11, 2021. The funds were contributed by private investors, including several investors who participated in the pre-seed round. BioLoomics will ...
